[Efficacy and Safety Profile of Ocriplasmin Treatment - an Update].

[Efficacy and Safety Profile of Ocriplasmin Treatment - an Update].
Klin Monbl Augenheilkd. 2017 Jun 09;:
Authors: Compera D, Priglinger S, Schumann RG
Abstract
Pharmacological vitreolysis with ocriplasmin is an effective treatment option for eyes with vitreomacular traction. Pre-marketing and post-marketing clinical studies revealed an improvement of visual function in ocriplasmin treated eyes and showed a release of traction in up to 78% of cases. Treatment success is related to patient selection based on positive predictive factors. Adverse events, such as visual acuity loss, dyschromatopsia or photopsia are known to be self-limited in the majority of eyes. Structural outer retinal layer changes, such as ellipsoid zone disturbances or subretinal fluid accumulation on SD-OCT analysis, as well as ERG abnormalities, are transient and correlated to VMT release. Surgical outcomes in patients with a prior history of ocriplasmin injection have been shown to be comparable with patients who proceeded directly to surgery without ocriplasmin treatment.
PMID: 28599332 [PubMed - as supplied by publisher]

Source: Klinische Monatsblatter fur Augenheilkunde - June 10, 2017 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research